Vincamine

CHEMBL1165342 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
354.4 g/mol
LogP
2.9
Phase
4

Vincamine is an indole alkaloid derived from the periwinkle plant Vinca minor that is a precursor to the synthetic derivative vinpocetine. It acts as a vasodilator and cerebral blood flow enhancer by inhibiting phosphodiesterase, reducing platelet aggregation, and relaxing vascular smooth muscle, thereby increasing oxygen and glucose delivery to brain tissue. It is used as a nootropic and circulatory supplement, primarily in Europe, for the treatment of cerebrovascular disorders, cognitive decline, and tinnitus.

Moleküler Ağırlık

354,4000 g/mol

LogP

2,90

TPSA

54,70 Ų

Lipinski RO5

Geçer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@]12CCCN3CCc4c(n(c5ccccc45)[C@@](O)(C(=O)OC)C1)[C@@H]32

InChI

InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1

Molecular Formula

C21H26N2O3

HBD / HBA

1 / 4

Döndürülebilir Bağlar

3

Ağır Atomlar

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Vincamine is an indole alkaloid derived from the periwinkle plant Vinca minor that is a precursor to the synthetic derivative vinpocetine. It acts as a vasodilator and cerebral blood flow enhancer by inhibiting phosphodiesterase, reducing platelet aggregation, and relaxing vascular smooth muscle, thereby increasing oxygen and glucose delivery to brain tissue. It is used as a nootropic and circulatory supplement, primarily in Europe, for the treatment of cerebrovascular disorders, cognitive decline, and tinnitus.

Yes, Vincamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1165342. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 15376. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.